Site Map
Contact Us
Disclaimer
Search
LATEST NEWS
2009, December 31
D-Pharm (DPRM: TASE) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI
2009, November 9
D-Pharm Enters into Collaboration with Wanbang Biopharmaceuticals to Increase the Potential Market for its Stroke Drug-Candidate DP-b99.
2009, August 17
D-Pharm raises NIS 85 Million in rights offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE).
DP-b99 a new treatment for acute stroke patients – short film English
Company Profile
Corporate Strategy
The Directors
Key Management
Therapeutic Focus & Market Size
Product Pipeline
Clinical Trials
Technologies
Patents
Reports & Regulatory Announcements
Calendar
Presentation & Factsheet
Advisors & Investors Contacts
FAQ
Latest News
Archived News
Israel